noscript

News and Announcements

Phylogica and cubist collaborate to evaluate antimicrobial phylomers

  • Published July 26, 2013 9:07AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

PERTH, AUSTRALIA: July 25th 2013. Phylogica Ltd (ASX: PYC, XETRA: PH7) a leading Australian peptide drug discovery company, announces a collaboration with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) to evaluate several of its antimicrobial Phylomers in models of multi-drug resistant bacterial infections.

“I am delighted to have the opportunity to collaborate with one of the world’s leading developers of antimicrobial drugs,” said Phylogica’s Chief Scientific Officer Dr Paul Watt. “Through this collaboration, we hope that Phylogica’s antimicrobial Phylomers will support Cubist’s ongoing work to discover and develop new antibiotics to address the growing global health threat of antibiotic resistance. In Phylogica’s own assays, these antimicrobials have shown activity against multi-resistant isolates of Gram- negative organisms, which are a major cause of deaths from hospital acquired infections of burn wounds”.

To read the full ASX announcement, please download the document below.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now